HE3286, an oral synthetic steroid, treats lung inflammation in mice without immune suppression

Journal of Inflammation

Volumn 7, Issue , 2010, Pages

  Conrad, Douglas ^a   Wang, Angela ^a   Pieters, Raymond ^b   Nicoletti, Ferdinando ^c   Mangano, Katia ^c   Van Heeckeren, Anna M ^d   White, Steven K ^e   Frincke, James M ^e   Reading, Christopher L ^e   Stickney, Dwight ^e   Auci, Dominick L ^e  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^b UTRECHT UNIVERSITY   (Netherlands)

^c UNIVERSITY OF CATANIA   (Italy)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Harbor Biosciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

16ALPHA BROMOEPIANDROSTERONE; 17ALPHA ETHYNYL 5 ANDROSTEN 3BETA, 7BETA, 17BETA TRIOL; ANTIINFLAMMATORY AGENT; HE 3286; OVALBUMIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; KLEBSIELLA PNEUMONIAE; LUNG INJURY; MALE; MOUSE; NEUTROPHIL COUNT; NONHUMAN; PLEURISY; PNEUMONIA;

ANIMALIA; MUS; RODENTIA;

EID: 77958611665     PISSN: None     EISSN: 14769255     Source Type: Journal    
DOI: 10.1186/1476-9255-7-52     Document Type: Article

References (68)

1. Mediators of chronic obstructive pulmonary disease. PJ Barnes, Pharmacol Rev 2004 56 515 48 10.1124/pr.56.4.2 15602009
2. Murine models of COPD. GG Brusselle KR Bracke T Maes AI D'Hulst KB Moerloose GF Joos,, et al. Pulm Pharmacol Ther 2006 19 155 65 10.1016/j.pupt.2005.06.001 16084119
3. The pathogenesis of COPD: lessons learned from in vivo animal models. M Fujita Y Nakanishi, Med Sci Monit 2007 13 A19 24 17261992
4. Lung inflammation as a therapeutic target in cystic fibrosis. DR Koehler GP Downey NB Sweezey AK Tanswell J Hu, Am J Respir Cell Mol Biol 2004 31 377 81 10.1165/rcmb.2004-0124TR 15381503
5. Role of neutrophils in mucus hypersecretion in COPD and implications for therapy. S Kim JA Nadel, Treat Respir Med 2004 3 147 59 10.2165/00151829- 200403030-00003 15219174
6. Monitoring inflammation in CF. Cytokines. SD Sagel FJ Accurso, Clin Rev Allergy Immunol 2002 23 41 57 10.1385/CRIAI:23:1:041 12162105
7. The role of inflammation in the pathophysiology of CF lung disease. JF Chmiel M Berger MW Konstan, Clin Rev Allergy Immunol 2002 23 5 27 10.1385/CRIAI:23:1:005 12162106
8. Health status measurement in COPD: the minimal clinically important difference of the clinical COPD questionnaire. JW Kocks MG Tuinenga SM Uil JW van den Berg E Stahl T van der Molen, Respir Res 2006 7 62 10.1186/1465-9921-7- 62 16603063
9. Treatment implications on morbidity and mortality in COPD. DW Mapel, Chest 2004 126 150S 8S discussion 9S-61S 10.1378/chest.126.2-suppl-1.150S 15302775
10. Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. SV Culpitt W Maziak S Loukidis JA Nightingale JL Matthews PJ Barnes, Am J Respir Crit Care Med 1999 160 1635 9 10556133
11. Antiinflammatory therapies for cystic fibrosis: past, present, and future. WA Prescott Jr CE Johnson, Pharmacotherapy 2005 25 555 73 10.1592/phco.25.4.555.61025 15977917
12. Inflammation and anti-inflammatory therapies for cystic fibrosis. JF Chmiel MW Konstan, Clin Chest Med 2007 28 331 46 10.1016/j.ccm.2007.02.002 17467552
13. The immunobiology and therapeutic potential of androstene hormones and their synthetic derivatives: novel anti-inflammatory and immune regulating steroid hormones. DL Auci C Ahlem M Li R Trauger C Dowding F Paillard,, et al. Mod Asp Immunobiol 2003 3 64 70
14. Estrogen-mediated regulation of CYP7B1: a possible role for controlling DHEA levels in human tissues. W Tang G Eggertsen JY Chiang M Norlin, J Steroid Biochem Mol Biol 2006 100 42 51 10.1016/j.jsbmb.2006.02.005 16720094
15. DHEA treatment: myth or reality? B Allolio W Arlt, Trends Endocrinol Metab 2002 13 288 94 10.1016/S1043-2760(02)00617-3 12163230
16. Relationship between insulin-like growth factor I, dehydroepiandrosterone sulfate and proresorptive cytokines and bone density in cystic fibrosis. CM Gordon E Binello MS LeBoff ME Wohl CJ Rosen AA Colin, Osteoporos Int 2006 17 783 90 10.1007/s00198-005-0058-x 16541207
17. Elevation of hepatic sulphotransferase activities in mice with resistance to cystic fibrosis. JL Falany H Greer T Kovacs EJ Sorscher CN Falany, Biochem J 2002 364 115 20 11988083
18. Dehydroepiandrosterone, dehydroepiandrosterone sulfate and related steroids: their role in inflammatory, allergic and immunological disorders. JS Dillon, Curr Drug Targets Inflamm Allergy 2005 4 377 85 10.2174/1568010054022079 16101547
19. Dehydroepiandrosterone (DHEA) supplementation for cognition and well-being. FA Huppert JK Van Niekerk J Herbert, Cochrane Database Syst Rev 2000 2 10796526
20. DHEA: panacea or snake oil? SM Sirrs RA Bebb, Can Fam Physician 1999 45 1723 8 10424272
21. Dehydroepiandrosterone - is the fountain of youth drying out? P Celec L Starka, Physiol Res 2003 52 397 407 12899651
22. Metabolism of DHEA by cytochromes P450 in rat and human liver microsomal fractions. JL Fitzpatrick SL Ripp NB Smith WM Pierce Jr RA Prough, Arch Biochem Biophys 2001 389 278 87 10.1006/abbi.2001.2341 11339818
23. Bioavailability and pharmacokinetics of dehydroepiandrosterone in the cynomolgus monkey. M Leblanc C Labrie A Belanger B Candas F Labrie, J Clin Endocrinol Metab 2003 88 4293 302 10.1210/jc.2003-022012 12970301
24. Postmenopausal steroid replacement with micronized dehydroepiandrosterone: preliminary oral bioavailability and dose proportionality studies. JE Buster PR Casson AB Straughn D Dale ES Umstot N Chiamori,, et al. Am J Obstet Gynecol 1992 166 1163 8 discussion 8-70 1533090
25. The actions of exogenous dehydroepiandrosterone in experimental animals and humans. F Svec JR Porter, Proc Soc Exp Biol Med 1998 218 174 91 9648935
26. Ergosteroids. VI. Metabolism of dehydroepiandrosterone by rat liver in vitro: a liquid chromatographic-mass spectrometric study. A Marwah P Marwah H Lardy, J Chromatogr B Biomed Sci Appl 2002 767 285 99 10.1016/S1570-0232(01) 00570-0 (Pubitemid 34142320)
27. Analysis of ergosteroids. VIII: Enhancement of signal response of neutral steroidal compounds in liquid chromatographic-electrospray ionization mass spectrometric analysis by mobile phase additives. A Marwah P Marwah H Lardy, J Chromatogr A 2002 964 137 51 10.1016/S0021-9673(02)00650-7 12198842
28. High-performance liquid chromatographic analysis of dehydroepiandrosterone. A Marwah P Marwah H Lardy, J Chromatogr A 2001 935 279 96 10.1016/S0021-9673(01)01268-7 11762780
29. In vitro potentiation of lymphocyte activation by dehydroepiandrosterone, androstenediol, and androstenetriol. DA Padgett RM Loria, J Immunol 1994 153 1544 52 8046232
30. A synthetic androstene derivative and a natural androstene metabolite inhibit relapsing-remitting EAE. H Offner A Zamora H Drought A Matejuk D Auci E Morgan,, et al. J Neuroimmunol 2002 130 128 10.1016/S0165-5728(02)00214-X 12225895
31. Antiglucocorticoid function of androstenetriol. RM Loria, Psychoneuroendocrinology 1997 22 103 8 10.1016/S0306-4530(97)00005-X 9264155
32. Androstenetriol and androstenediol: Protection against lethal radiation and restoration of immunity after radiation injury. RM Loria DH Conrad T Huff H Carter D Ben-Nathan, Ann N Y Acad Sci 2000 917 860 7 10.1111/j.1749-6632.2000. tb05452.x 11268417
33. Transformation in vitro of [4-14-C]-dehydroepiandrosterone into 7-oxygenated derivatives by normal human male and female skin tissue. I Faredin AG Fazekas I Toth K Kokai M Julesz, J Invest Dermatol 1969 52 357 61 4238085
34. In vitro metabolism of (4-14C)-androsten-3b,17b-diol in healthy human skin. I Faredin I Toth, Kiserletes Orvostudomany 1975 27 32 45
35. Redox reactions of dehydroepiandrosterone and its metabolites in differentiating 3T3-L1 adipocytes: A liquid chromatographic-mass spectrometric study. A Marwah FE Gomez P Marwah JM Ntambi BG Fox H Lardy, Arch Biochem Biophys 2006 456 1 7 10.1016/j.abb.2006.09.023 17078923
36. Mobilization of cutaneous immunity for systemic protection against infections. RM Loria DA Padgett, Ann N Y Acad Sci 1992 650 363 6 10.1111/j.1749-6632.1992.tb49153.x 1318664
37. The identification and simultaneous quantification of 7-hydroxylated metabolites of pregnenolone, dehydroepiandrosterone, 3beta,17beta- androstenediol, and testosterone in human serum using gas chromatography-mass spectrometry. M Hill H Havlikova J Vrbikova R Kancheva L Kancheva V Pouzar,, et al. J Steroid Biochem Mol Biol 2005 96 187 200 10.1016/j.jsbmb.2005.02.009 15908198
38. Steroid and sterol 7-hydroxylation: ancient pathways. R Lathe, Steroids 2002 67 967 77 10.1016/S0039-128X(02)00044-2 12398993
39. Inflammation and sex hormone metabolism. M Schmidt H Naumann C Weidler M Schellenberg S Anders RH Straub, Ann N Y Acad Sci 2006 1069 236 46 10.1196/annals.1351.021 16855150
40. 7-Hydroxy androstene steroids and a novel synthetic analogue with reduced side effects as a potential agent to treat autoimmune diseases. DL Auci CL Reading JM Frincke, Autoimmun Rev 2009 8 369 72 10.1016/j.autrev.2008.11.011 19071234
41. A new orally bioavailable syntheic androstene inhibits collagen-induced arthritis in the mouse. D Auci L Kaler S Subramanian Y Huang J Frincke C Reading,, et al. Ann N Y Acad Sci 2007 1110 630 40 10.1196/annals.1423.066 17911478
42. Oral treatment with HE3286 ameliorates disease in rodent models of rheumatoid arthritis. D Auci K Mangano D Destiche SK White Y Haung D Boyle,, et al. 2010 625 33 20198312
43. HE3286: a novel sythetic steroid as an oral treatment for autoimmune disease. C Ahlem D Auci K Mangano C Reading J Frincke D Stickney,, et al. Ann N Y Acad Sci 2009 19758229
44. Biological properties of carrageenan. M Di Rosa, J Pharm Pharmacol 1972 24 89 102 4402944
45. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. JE Krawisz P Sharon WF Stenson, Gastroenterology 1984 87 1344 50 6092199
46. Role of Cftr genotype in the response to chronic Pseudomonas aeruginosa lung infection in mice. AM van Heeckeren MD Schluchter ML Drumm PB Davis, Am J Physiol Lung Cell Mol Physiol 2004 287 944 52 10.1152/ajplung.00387.2003 15246977
47. Delivery of CFTR by adenoviral vector to cystic fibrosis mouse lung in a model of chronic Pseudomonas aeruginosa lung infection. AM Van Heeckeren A Scaria MD Schluchter TW Ferkol S Wadsworth PB Davis, Am J Physiol Lung Cell Mol Physiol 2004 286 717 26 10.1152/ajplung.00227.2003 14514520
48. Murine models of chronic Pseudomonas aeruginosa lung infection. AM van Heeckeren MD Schluchter, Lab Anim 2002 36 291 312 10.1258/002367702320162405 12144741
49. Effect of Pseudomonas infection on weight loss, lung mechanics, and cytokines in mice. AM van Heeckeren J Tscheikuna RW Walenga MW Konstan PB Davis B Erokwu,, et al. Am J Respir Crit Care Med 2000 161 271 9 10619831
50. SAS/STAT user's guide, SAS OnlineDoc 9.1. SAS Institute Inc, SAS Institute, Inc 2004
51. An orally bioavailable synthetic analog of an active dehydroepiandrosterone metabolite reduces established disease in rodent models of rheumatoid arthritis. H Offner GS Firestein DL Boyle R Pieters JM Frincke A Garsd,, et al. J Pharmacol Exp Ther 2009 329 1100 9 10.1124/jpet.108.145086 19297421
52. IgE isotype switch and IgE production are enhanced in IL-21-deficient but not IFN-gamma-deficient mice in a Th2-biased response. XZ Shang KY Ma J Radewonuk J Li XY Song DE Griswold,, et al. Cell Immunol 2006 241 66 74 10.1016/j.cellimm.2006.07.011 16979605
53. Pulmonary and systemic host response to Streptococcus pneumoniae and Klebsiella pneumoniae bacteremia in normal and immunosuppressed mice. E Wang N Ouellet M Simard I Fillion Y Bergeron D Beauchamp,, et al. Infect Immun 2001 69 5294 304 10.1128/IAI.69.9.5294-5304.2001 11500398
54. Lung infections associated with cystic fibrosis. JB Lyczak CL Cannon GB Pier, Clin Microbiol Rev 2002 15 194 222 10.1128/CMR.15.2.194-222.2002 11932230
55. 16alpha-Bromoepiandrosterone (HE2000) limits non-productive inflammation and stimulates immunity in lungs. F Nicoletti D Conrad A Wang R Pieters K Mangano A van Heeckeren,, et al. Clin Exp Immunol 2009
56. The role of aquaporin-1 (AQP1) expression in a murine model of lipopolysaccharide-induced acute lung injury. X Su Y Song J Jiang C Bai, Respir Physiol Neurobiol 2004 142 1 11 10.1016/j.resp.2004.05.001 15351300
57. Lipopolysaccharide-induced lung injury in mice. I. Concomitant evaluation of inflammatory cells and haemorrhagic lung damage. C Asti V Ruggieri S Porzio R Chiusaroli G Melillo GF Caselli, Pulm Pharmacol Ther 2000 13 61 9 10.1006/pupt.2000.0231 10799283
58. Acute lung injury: what have we learned from animal models? AC Windsor PG Mullen AA Fowler, Am J Med Sci 1993 306 111 6 10.1097/00000441-199308000-00010 8362891
59. Src tyrosine kinases mediate activations of NF-kappaB and integrin signal during lipopolysaccharide-induced acute lung injury. HS Lee C Moon HW Lee EM Park MS Cho JL Kang, J Immunol 2007 179 7001 11 17982091
60. Matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in the respiratory tract: potential implications in asthma and other lung diseases. MM Gueders JM Foidart A Noel DD Cataldo, Eur J Pharmacol 2006 533 133 44 10.1016/j.ejphar.2005.12.082 16487964
61. A new antidiabetic compound attenuates inflammation and insulin resistance in Zucker diabetic fatty rats. M Lu D Patsouris P Li J Flores-Riveros JM Frincke S Watkins,, et al. Am J Physiol Endocrinol Metab 2010 298 1036 48 10.1152/ajpendo.00668.2009 20159859
62. The biological actions of dehydroepiandrosterone involves multiple receptors. SJ Webb TE Geoghegan RA Prough KK Michael Miller, Drug Metab Rev 2006 38 89 116 10.1080/03602530600569877 16684650
63. Physiological importance of dehydroepiandrosterone. P Ebeling VA Koivisto, Lancet 1994 343 1479 81 10.1016/S0140-6736(94)92587-9 7911183
64. Amelioration of glucose intolerance by the synthetic androstene HE3286: link to inflammatory pathways. T Wang S Villegas Y Huang SK White C Ahlem M Lu,, et al. J Pharmacol Exp Ther 2010 333 70 80 10.1124/jpet.109.161182 20068030
65. HE3286: a novel synthetic steroid as an oral treatment for autoimmune disease. C Ahlem D Auci K Mangano C Reading J Frincke D Stickney,, et al. Ann N Y Acad Sci 2009 1173 781 90 10.1111/j.1749-6632.2009.04798.x 19758229
66. Diabetes: a major co-morbidity of cystic fibrosis. M Costa S Potvin Y Berthiaume L Gauthier A Jeanneret A Lavoie,, et al. Diabetes Metab 2005 31 221 32 10.1016/S1262-3636(07)70189-1 16142013
67. Diabetes is associated with dramatically decreased survival in female but not male subjects with cystic fibrosis. CE Milla J Billings A Moran, Diabetes Care 2005 28 2141 4 10.2337/diacare.28.9.2141 16123480
68. Inflammation and the etiology of type 2 diabetes. A Sjoholm T Nystrom, Diabetes Metab Res Rev 2006 22 4 10 10.1002/dmrr.568 15991254